within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A03A_DrugsForFunctionalGastrointestinalDisorders.A03AE01_Alosetron;

model Alosetron
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 6.11111111111111e-06,
    adminDuration = 600,
    adminMass = 1 / 1000000,
    adminCount = 1,
    Vd = 0.065,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.02,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Alosetron</td></tr><tr><td>ATC code:</td><td>A03AE01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>65</td><td>L</td></tr>
    <tr><td>clearance:</td><td>22</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Alosetron is a potent and selective 5-HT3 receptor antagonist indicated for the treatment of severe diarrhea-predominant irritable bowel syndrome (IBS-D) in women who have not responded to conventional therapy. It is approved for restricted use in some countries due to concerns about rare but serious gastrointestinal adverse effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers, both male and female, after a single oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A03AE01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Alosetron;
